Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH) A Randomized, Controlled, Double-blind, Parallel Group, Proof-of-concept Trial EDITA

Next Previous
Trial Profile

Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH) A Randomized, Controlled, Double-blind, Parallel Group, Proof-of-concept Trial EDITA

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ambrisentan (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Proof of concept; Therapeutic Use
  • Acronyms EDITA

Most Recent Events

  • 18 Jul 2024 Results assessing long-term effects of open label therapy with ambrisentan vs. no pulmonary arterial hypertension , published in the Arthritis Research and Therapy.
  • 17 Apr 2020 Status changed from active, no longer recruiting to completed.
  • 19 Sep 2018 Results presented at the 28th Annual Congress of the European Respiratory Society

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top